DOCSLIB.ORG

Membrane Transporter/Ion Channel Compound Library (96-Well)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Membrane Transporter/Ion Channel Compound Library (96-Well) • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Membrane Transporter/Ion Channel Compound Library (96-well) Product Details: Catalog Number: CS-L011 Formulation: A collection of 849 Membrane Transporter/Ion Channel related compounds supplied as pre-dissolved Solutions or Solid Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: CS-L011-1 1 2 3 4 5 6 7 8 9 10 11 12 SKF-96365 Varenicline a Empty (hydrochlorid Vonoprazan BAY-876 Ko 143 JNJ- Pipequaline PAP-1 Varenicline (Hydrochlorid HC-067047 Empty e) 17203212 e) SKF89976A ML133 DMCM b Empty Varenicline (hydrochlorid (hydrochlorid Naminidil MCHR1 (hydrochlorid MRK-016 Nigericin (S)- Linaprazan Empty (Tartrate) e) e) antagonist 2 e) (sodium salt) ML753286 LY2365109 D-α- c Empty (hydrochlorid ZL006 IC87201 A-804598 Hydroxyglutar BAPTA-AM Abscisic acid CaCCinh-A01 T16Ainh-A01 U93631 Empty e) ic acid Norverapamil (-)-Bicuculline Pirmenol d Empty D-AP5 GSK2193874 AM-2099 (hydrochlorid (methobromid gamma-DGG (hydrochlorid Kynurenic Quinolinic D-Serine Empty e) e) e) acid acid Isoguvacine 7- 7- (RS)-AMPA Diphenylenei Adenosine 5′- e Empty Guvacine (hydrochlorid Chlorokynure Chlorokynure (monohydrate YM-58483 odonium diphosphorib FG 7142 NPPB Empty hydrochloride e) nic acid nic acid ) chloride ose (sodium) 8-Bromo- 4- f Empty Sarcosine Y-26763 MK-8998 Org-26576 DHBP ZD7288 cGMP PF-01247324 ICA-069673 Acetamidobut Empty (dibromide) (sodium) anoic acid Vanilpyruvic JNJ- Polyoxyethyle g Empty L-DABA acid 47965567 GAL-021 NS-638 Ralfinamide CDN1163 Pico145 ne stearate TRPC6-IN-1 Empty CP-409092 EIPA h Empty Gefapixant (hydrochlorid Ilaprazole AMG9810 EIPA (hydrochlorid ML213 Fasentin ASP7663 PSB-12062 Empty e) e) Plate layout: CS-L011-2 1 2 3 4 5 6 7 8 9 10 11 12 Gaboxadol GYKI 53655 a Empty CM-4620 Apimostinel NS13001 THIP (hydrochlorid CLP290 Zuranolone (hydrochlorid SCH28080 ML218 Empty e) e) Fasudil b Empty MRS1845 Bepridil trans-Ned 19 Eact Talniflumate DCPIB (Hydrochlorid Ro15-4513 (S)- CGP52432 Empty hydrochloride e) SNAP5114 SSD114 Dapagliflozin c Empty Gabazine (hydrochlorid TTA-Q6 ML335 NecroX-5 ML402 Capsaicin Capsaicinoid Dapagliflozin ((2S)-1,2- Empty e) propanediol, ABT-418 Tariquidar d Empty Canagliflozin Fantofarone (hydrochlorid Loreclezole PF 04531083 Piromelatine Tariquidar (methanesulf Ketanserin Ketanserin Empty e) onate, (tartrate) Eniporide Nelonemdaz e Empty BNC210 Bay K 8644 Endovion Zamicastat hydrochloride SB-705498 AMG 517 HMR 1556 Nelonemdaz (potassium) Empty Caroverine (2S)-6- Barnidipine f Empty (hydrochlorid PF-03463275 Prenylnaringe Selamectin Almitrine Azosemide (hydrochlorid SKA-121 LE135 Kynurenic Empty e) nin mesylate e) acid (sodium) WAY-213613 α-Cyano-4- Desformylflus Aminooxyacet g Empty DL-TBOA (hydrochlorid AS1269574 UBP310 hydroxycinna SN 6 trabromine SIB-1553A SEN12333 ic acid Empty e) mic acid hydrochloride (hemihydrochl Facinicline Lanicemine CP-100356 h Empty Mirogabalin ABT-107 (hydrochlorid Bitopertin (dihydrochlori (Rac)- Pivagabine AM-0902 (hydrochlorid WS-12 Empty besylate e) de) Lanicemine e) Plate layout: CS-L011-3 1 2 3 4 5 6 7 8 9 10 11 12 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 732-484-9848 Fax: 888-484-5008 Email: [email protected] • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com XE 991 a Empty ML-SA1 A-967079 Pyr3 QX-314 P-1075 dihydrochlorid Flindokalner VU591 VU591 NS5806 Empty (chloride) e hydrochloride AZ10606120 b Empty DMP-543 BMS-191011 PD-118057 BL-1249 (dihydrochlori Broflanilide Fluxametamid LY3130481 Lavendustin NSC 15364 Empty de) e B (R)- c Empty Dotinurad Tulrampator Licogliflozin Posenacaftor Posenacaftor Aniracetam CX516 Mibampator LY450108 S 18986 Empty (sodium) (sodium) NS8593 d Empty Farampator (hydrochlorid VU0463271 ZSET1446 NS19504 Risperidone ML 297 CIM0216 BX430 MK6-83 Empty e) (Rac)- e Empty NS11394 Icilin A-803467 AZD7325 GSK1702934 GLPG1837 JT010 Synta66 NMDAR Pinaverium Empty A antagonist 1 bromide JNJ- PSEM 89S TRPM8 IK1 inhibitor f Empty Gboxin SKA-31 PTI-428 61432059 BI-749327 PF-06869206 (TFA) HC-070 antagonist 2 PA-6 Empty L- L- L- Taurolithochol RO2959 g Empty AMG 333 ACT-709478 ONO- Palmitoylcarni Palmitoylcarni Palmitoylcarni ic acid Etiocholanolo (monohydroc Azumolene Empty 8590580 tine tine (chloride) tine (TFA) (sodium salt) ne hloride) TRPV4 Propiverine h Empty GDC-0276 (-)-(S)-B- PF-06305591 PF-06305591 GT 949 agonist-1 DS16570511 (hydrochlorid Metaflumizon Lotilaner Empty 973B (dihydrate) (free base) e) e Plate layout: CS-L011-4 1 2 3 4 5 6 7 8 9 10 11 12 N-(p- Empty AUT1 VU041 amylcinnamo Tifenazoxide Cav 2.2 Bifenazate GLPG2451 Afizagabar ML67-33 GSK205 Empty a yl) Anthranilic blocker 1 GSK369796 Bevantolol Tipepidine b Empty Dihydrochlori PF-06372865 (hydrochlorid A-867744 CCMI NS 1738 PNU-120596 CGP 36742 (Rac)-MEM (hydrochlorid Empty de e) 1003 e) VU0134992 c Empty Valnoctamide ABT-239 ASP2905 AC1903 ICA-27243 BAY-8002 SB-366791 (hydrochlorid Aurintricarbox TRPM4-IN-1 Empty e) ylic acid PEAQX d Empty ML418 Rostafuroxin (tetrasodium Oxatomide ISX-9 ML277 ML365 ORM-10962 KGA-2727 VU0071063 Empty hydrate) (Rac)-ABT- Efonidipine Naspm e Empty 202 BI 01383298 NS-1619 GV-58 (hydrochlorid CFM-2 Pyr6 CX546 Naspm (trihydrochlori Empty (dihydrochlori e de) Nicardipine Dantrolene f Empty GSK-7975A DSP-2230 PEPA (hydrochlorid GSK-5498A Astemizole Disopyramide CFTR (sodium PNU-282987 Empty e) corrector 2 hemiheptahy Sigma-1 D- g Empty receptor Tubocurarine GS967 Quisqualic Nav1.1 Mirogabalin R(+)-IAA-94 VU0810464 LDN-212320 AZD3965 Empty antagonist 3 (chloride acid activator 1 5-(N,N- h Empty YHO-13177 YHO-13351 Raxatrigine Hexamethyle Optovin PF-04856264 BNC375 ORM-10103 WEHI-9625 Eliprodil Empty (free base) hydrochloride ne)-amiloride Plate layout: CS-L011-5 1 2 3 4 5 6 7 8 9 10 11 12 ML204 Dibutyryl- a Empty Ifenprodil PF 05089771 EN6 BPAM344 Clomethiazol ML204 (hydrochlorid NMDA-IN-1 Ivacaftor cGMP Empty (tartrate) e e) (sodium) SDZ 220-581 b Empty SDZ 220-581 (hydrochlorid BAY-1797 Isotachysterol NS 11021 DS-1971a TPC2-A1-N TPC2-A1-P Rivanicline AR-C155858 Empty e) 3 hemioxalate GABAA Zatebradine c Empty Lumacaftor KN-62 Vinpocetine nAChR GFB-8438 receptor Lu AE98134 Tofogliflozin (hydrochlorid Zatebradine Empty agonist 1 agent 1 (hydrate) e) Ethacizine (R)-Verapamil (S)-Verapamil A2764 d Empty Ionomycin Indophagolin ML-SI1 (hydrochlorid TRAM-34 (hydrochlorid (hydrochlorid OR-1896 (dihydrochlori Urolithin C Empty (calcium) e) e) e) de) BzATP AMPA e Empty Cisatracurium P2X3 H3B-120 SUVN-911 (triethylammo receptor Sepimostat MDR-652 Encequidar Encequidar Empty (besylate) antagonist 34 nium salt) modulator-2 (mesylate) 5- (S)-UFR2709 f Empty Hydroxydeca Lansoprazole (R)- SR33805 Methionine Oleandrin COR659 (hydrochlorid (E/Z)- Ebselen Empty noate Lansoprazole e) Sivopixant Vernakalant Amiodarone g Empty A2793 Tetrandrine Spinosad A 839977 Nav1.7 Ro 25-6981 PPQ-102 (Hydrochlorid (hydrochlorid Levcromakali Empty inhibitor (Maleate) e) e) m Gallopamil Tebanicline GTS-21 h Empty Verapamil (hydrochlorid Nilvadipine Levosimenda Pinacidil (dihydrochlori L-655708 NP118809 AF-353 (dihydrochlori Empty e) n monohydrate de) de) Plate layout: CS-L011-6 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 732-484-9848 Fax: 888-484-5008 Email: [email protected] • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com 1 2 3 4 5 6 7 8 9 10 11 12 L-Glutamic Diltiazem a Empty Rosiglitazone L-Glutamic acid (hydrochlorid Levamlodipin Monepantel Radiprodil Ataluren Ipragliflozin Remogliflozin Empty (maleate) acid (monosodium e) e besylate etabonate Chembridge- Fanapanel Dizocilpine b Empty Imepitoin HC-030031 5861528 CNQX DNQX NBQX Fanapanel hydrate Talampanel (maleate) Empty (-)-Dizocilpine (S)-(-)-Bay-K- (R)-(+)-Bay- Glibenclamid Lesinurad Vonoprazan c Empty (maleate) MDL 105519 8644 K-8644 e Lesinurad (sodium) (Fumarate) Vigabatrin Empagliflozin Empty Ertugliflozin GW791343 A 438079 d Empty KB-R7943 NS309 Encenicline Tezacaftor Ertugliflozin L- (dihydrochlori A 438079 (hydrochlorid SEA0400 Empty (mesylate) hydrochloride pyroglutamic de) e) Mibefradil A-317491 LY 303511 e Empty Sotagliflozin S0859 E-4031 (dihydrochlori APD668 A-317491 (sodium salt GW9508 Capsazepine (hydrochlorid Empty de) hydrate) e) SAR7334 Istaroxime Carboxyamid f Empty SAR7334 (hydrochlorid QNZ46 NS6180 (hydrochlorid CGP37157 NBI-98782 BTB06584 Tenapanor otriazole Empty e) e) (Orotate) D-3263 Etifoxine g Empty Carboxyamid (hydrochlorid Gabapentin MDL-29951 Minodronic Transcrocetin (hydrochlorid Etifoxine Oligomycin A CFTR(inh)- Empty otriazole e) enacarbil acid ate disodium e) 172 (S)-(-)-5- Rapastinel Eleclazine h Empty VU 0240551 SN 2 Fluorowillardii Basmisanil Funapide (R)-Funapide (Trifluoroacet Verinurad (hydrochlorid Valbenazine Empty ne ate) e) Plate layout: CS-L011-7 1 2 3 4 5 6 7 8 9 10 11 12 Bepridil a Empty ICA-121431 RPR-260243 NS1643 Mavatrep (hydrochlorid JNJ 303 Afoxolaner Flupirtine Dofequidar Acamprosate Empty e hydrate) (Maleate) (fumarate) (calcium) Ranolazine Manidipine b Empty (R)-Baclofen Atazanavir Rosiglitazone (-)-Huperzine Mitiglinide (dihydrochlori (dihydrochlori Cilnidipine Flecainide Clevidipine Empty (sulfate) A (calcium) de) de) (acetate) Mefloquine Pantoprazole Meclofenoxat c Empty (hydrochlorid Omberaceta Bumetanide Rosuvastatin Pantoprazole (sodium Sunifiram Coluracetam e Nonivamide Empty e) m (Calcium) (sodium) hydrate) (hydrochlorid Radafaxine
Load more

Recommended publications
  • Effects of Chronic Systemic Low-Impact Ampakine Treatment On
    Biomedicine & Pharmacotherapy 105 (2018) 540–544 Contents lists available at ScienceDirect Biomedicine & Pharmacotherapy journal homepage: www.elsevier.com/locate/biopha Effects of chronic systemic low-impact ampakine treatment on neurotrophin T expression in rat brain ⁎ Daniel P. Radin , Steven Johnson, Richard Purcell, Arnold S. Lippa RespireRx Pharmaceuticals, Inc., 126 Valley Road, Glen Rock, NJ, 07452, United States ARTICLE INFO ABSTRACT Keywords: Neurotrophin dysregulation has been implicated in a large number of neurodegenerative and neuropsychiatric Ampakine diseases. Unfortunately, neurotrophins cannot cross the blood brain barrier thus, novel means of up regulating BDNF their expression are greatly needed. It has been demonstrated previously that neurotrophins are up regulated in Cognitive enhancement response to increases in brain activity. Therefore, molecules that act as cognitive enhancers may provide a LTP clinical means of up regulating neurotrophin expression. Ampakines are a class of molecules that act as positive Neurotrophin allosteric modulators of AMPA-type glutamate receptors. Currently, they are being developed to prevent opioid- NGF induced respiratory depression without sacrificing the analgesic properties of the opioids. In addition, these molecules increase neuronal activity and have been shown to restore age-related deficits in LTP in aged rats. In the current study, we examined whether two different ampakines could increase levels of BDNF and NGF at doses that are active in behavioral measures of cognition. Results demonstrate that ampakines CX516 and CX691 induce differential increases in neurotrophins across several brain regions. Notable increases in NGF were ob- served in the dentate gyrus and piriform cortex while notable BDNF increases were observed in basolateral and lateral nuclei of the amygdala.
    [Show full text]
  • Molecular Mechanisms Underlying Ketamine-Mediated Inhibition Of
    Anesthesiology 2005; 102:93–101 © 2004 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Molecular Mechanisms Underlying Ketamine-mediated Inhibition of Sarcolemmal Adenosine Triphosphate- sensitive Potassium Channels Takashi Kawano, M.D.,* Shuzo Oshita, M.D.,† Akira Takahashi, M.D.,‡ Yasuo Tsutsumi, M.D.,* Katsuya Tanaka, M.D.,§ Yoshinobu Tomiyama, M.D.,࿣ Hiroshi Kitahata, M.D.,# Yutaka Nakaya, M.D.** Background: Ketamine inhibits adenosine triphosphate-sen- sensitive channel pore.3 These channels, as metabolic sitive potassium (KATP) channels, which results in the blocking sensors, are associated with such cellular functions as of ischemic preconditioning in the heart and inhibition of va- insulin secretion, cardiac preconditioning, vasodilata- sorelaxation induced by KATP channel openers. In the current 4–7 Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/102/1/93/357819/0000542-200501000-00017.pdf by guest on 27 September 2021 study, the authors investigated the molecular mechanisms of tion, and neuroprotection. ketamine’s actions on sarcolemmal KATP channels that are re- In cardiac myocytes, intravenous general anesthetics, associated by expressed subunits, inwardly rectifying potas- such as ketamine racemate, propofol, and thiamylal, di- sium channels (Kir6.1 or Kir6.2) and sulfonylurea receptors 8–10 rectly inhibit native sarcolemmal KATP channels. Al- (SUR1, SUR2A, or SUR2B). though these observations suggest that intravenous an- Methods: The authors used inside-out patch clamp configura- tions to investigate the effects of ketamine on the activities of esthetics may impair the endogenous organ protective reassociated Kir6.0/SUR channels containing wild-type, mutant, mechanisms mediated by KATP channels, the possibility or chimeric SURs expressed in COS-7 cells.
    [Show full text]
  • Role of Prefrontal Cortex and Cholinergic Modulation in Attentional
    Role of prefrontal cortex and cholinergic modulation in attentional performance in rats Beth Mary Fisher Department of Psychology Downing College University of Cambridge September 2017 This dissertation is submitted for the degree of Doctor of Philosophy Declaration This dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration except as declared in the Preface and specified in the text. It is not substantially the same as any that I have submitted, or, is being concurrently submitted for a degree or diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. I further state that no substantial part of my dissertation has already been submitted, or, is being concurrently submitted for any such degree, diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. It does not exceed the prescribed word limit of the degree committee for the faculty of biology of 60,000 words. i2 Acknowledgements Firstly, I would like to thank my supervisor Tim Bussey and advisor Trevor Robbins for their invaluable support, guidance and encouragement throughout my PhD. Their insightful scientific discussions, passion for the field and praise of me, have shaped me to become a scientist I am proud of, and given me an unknown confidence. Not only are they experts in the field, but they are down to earth, kind and fun.
    [Show full text]
  • Edison Healthcare Insight
    Edison Healthcare Insight December 2020 Published by Edison Investment Research The Edison healthcare team www.edisongroup.com Maxim Jacobs Dr Nathaniel Calloway Max joined Edison’s healthcare team in December Nathaniel Calloway joined the healthcare team in 2014. Prior to this he worked as a senior analyst at December 2015. Before Edison, he performed Guidepoint Global. Max has also previously worked healthcare investment research for a fund at Bishop as a senior analyst at Ridgemark Capital, a sector Rosen and for Wainscott Capital Partners. Prior to head at Broadfin Capital and as a senior analyst at his role as an analyst he performed molecular Mehta Partners. He is a CFA charter holder. neuroscience research at Cornell Medical School and holds a PhD in chemistry from Cornell. He has published eight scientific papers on topics ranging from physical chemistry to immunology, and he has been recognised as an American Heart Association fellow and an American Chemical Society Medicinal Chemistry fellow. Pooya Hemami Dr John Savin Pooya is a licensed optometrist with over five years John is an analyst working on biotech, pharma, of experience in life sciences equity research. Prior medical device and diagnostics companies. As to joining Edison, he covered the Canadian founder CEO of Physiomics, he devised the healthcare sector as a research analyst at strategy, raised funds and took the company to AIM Desjardins Capital Markets. He holds a doctor of in 2004. At Greig Middleton, John was director in optometry degree from the University of Montreal, charge of the pharma and biotech analyst team and and an MBA (finance concentration) from McGill worked with corporate finance on fund-raising, IPOs University.
    [Show full text]
  • Summary Analgesics Dec2019
    Status as of December 31, 2019 UPDATE STATUS: N = New, A = Advanced, C = Changed, S = Same (No Change), D = Discontinued Update Emerging treatments for acute and chronic pain Development Status, Route, Contact information Status Agent Description / Mechanism of Opioid Function / Target Indication / Other Comments Sponsor / Originator Status Route URL Action (Y/No) 2019 UPDATES / CONTINUING PRODUCTS FROM 2018 Small molecule, inhibition of 1% diacerein TWi Biotechnology / caspase-1, block activation of 1 (AC-203 / caspase-1 inhibitor Inherited Epidermolysis Bullosa Castle Creek Phase 2 No Topical www.twibiotech.com NLRP3 inflamasomes; reduced CCP-020) Pharmaceuticals IL-1beta and IL-18 Small molecule; topical NSAID Frontier 2 AB001 NSAID formulation (nondisclosed active Chronic low back pain Phase 2 No Topical www.frontierbiotech.com/en/products/1.html Biotechnologies ingredient) Small molecule; oral uricosuric / anti-inflammatory agent + febuxostat (xanthine oxidase Gout in patients taking urate- Uricosuric + 3 AC-201 CR inhibitor); inhibition of NLRP3 lowering therapy; Gout; TWi Biotechnology Phase 2 No Oral www.twibiotech.com/rAndD_11 xanthine oxidase inflammasome assembly, reduced Epidermolysis Bullosa Simplex (EBS) production of caspase-1 and cytokine IL-1Beta www.arraybiopharma.com/our-science/our-pipeline AK-1830 Small molecule; tropomyosin Array BioPharma / 4 TrkA Pain, inflammation Phase 1 No Oral www.asahi- A (ARRY-954) receptor kinase A (TrkA) inhibitor Asahi Kasei Pharma kasei.co.jp/asahi/en/news/2016/e160401_2.html www.neurosmedical.com/clinical-research;
    [Show full text]
  • Central Valley Toxicology Drug List
    Chloroform ~F~ Lithium ~A~ Chlorpheniramine Loratadine Famotidine Acebutolol Chlorpromazine Lorazepam Fenoprofen Acetaminophen Cimetidine Loxapine Fentanyl Acetone Citalopram LSD (Lysergide) Fexofenadine 6-mono- Clomipramine acetylmorphine Flecainide ~M~ Clonazepam a-Hydroxyalprazolam Fluconazole Maprotiline Clonidine a-Hydroxytriazolam Flunitrazepam MDA Clorazepate Albuterol Fluoxetine MDMA Clozapine Alprazolam Fluphenazine Medazepam Cocaethylene Amantadine Flurazepam Meperidine Cocaine 7-Aminoflunitrazepam Fluvoxamine Mephobarbital Codeine Amiodarone Fosinopril Meprobamate Conine Amitriptyline Furosemide Mesoridazine Cotinine Amlodipine Methadone Cyanide ~G~ Amobarbital Methanol Cyclobenzaprine Gabapentin Amoxapine d-Methamphetamine Cyclosporine GHB d-Amphetamine l-Methamphetamine Glutethamide l-Amphetamine ~D~ Methapyrilene Guaifenesin Aprobarbital Demoxepam Methaqualone Atenolol Desalkylfurazepam ~H~ Methocarbamol Atropine Desipramine Halazepam Methylphenidate ~B~ Desmethyldoxepin Haloperidol Methyprylon Dextromethoraphan Heroin Metoclopramide Baclofen Diazepam Hexobarbital Metoprolol Barbital Digoxin Hydrocodone Mexiletine Benzoylecgonine Dihydrocodein Hydromorphone Midazolam Benzphetamine Dihydrokevain Hydroxychloroquine Mirtazapine Benztropine Diltiazem Hydroxyzine Morphine (Total/Free) Brodificoum Dimenhydrinate Bromazepam ~N~ Diphenhydramine ~I~ Bupivacaine Nafcillin Disopyramide Ibuprofen Buprenorphine Naloxone Doxapram Imipramine Bupropion Naltrexone Doxazosin Indomethacin Buspirone NAPA Doxepin Isoniazid Butabarbital Naproxen
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Fantofarone Item No. 26381 CAS Registry No.: 114432-13-2 Formal Name: 3,4-dimethoxy-N-methyl-N-[3-[4-[[2- N (1-methylethyl)-1-indolizinyl]sulfonyl] O phenoxy]propyl]-benzeneethanamine S O Synonym: SR 33557 MF: C31H38N2O5S FW: 550.7 Purity: ≥98% N O UV/Vis.: λmax: 233, 304 nm Supplied as: A crystalline solid O Storage: -20°C O Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Fantofarone is supplied as a crystalline solid. A stock solution may be made by dissolving the fantofarone in the solvent of choice. Fantofarone is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of fantofarone in these solvents is approximately 10 mg/ml. Description Fantofarone is a calcium channel inhibitor.1 It selectively inhibits the L-type voltage-gated calcium channel in isolated rat aorta (IC50 = 0.61 nM) over α1- and β-adrenergic, muscarinic, and histamine H2 receptors in rat heart homogenates (IC50s = >10, >10, 4, and >10 µM, respectively), and the serotonin receptor subtypes 5-HT1 and 5-HT2, as well as histamine H1 and adenosine A1 receptors, in rat brain homogenates (IC50s = >10, 4, >10, and >10 µM, respectively). Fantofarone inhibits peak calcium current in depolarized 2 and hyperpolarized L-type voltage-gated calcium channels (IC50s = 1.4 and 150 nM, respectively). It inhibits potassium chloride- and norepinephrine-induced contractions in isolated rat aorta (IC50s = 5.64 and 96 nM, respectively).1 It enhances recovery of cardiac output during reperfusion of isolated rat hearts when used at a concentration of 10 nM.3 Fantofarone prevents angioplasty-induced vasospasms in the femoral artery in a rabbit model of focal atherosclerosis when administered at a dose of 50 µg/kg.4 References 1.
    [Show full text]
  • Hayward Et Al, 2017
    European Neuropsychopharmacology (]]]]) ], ]]]–]]] www.elsevier.com/locate/euroneuro Partial agonism at the α7 nicotinic acetylcholine receptor improves attention, impulsive action and vigilance in low attentive rats Andrew Haywardn, Lisa Adamson, Joanna C. Neilln Division of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Manchester M13 9PT, UK Received 7 July 2016; received in revised form 9 January 2017; accepted 18 January 2017 KEYWORDS Abstract 5 choice-continuous Inattention is a disabling symptom in conditions such as schizophrenia and attention deficit/ performance task; hyperactivity disorder. Nicotine can improve attention and vigilance, but is unsuitable for clinical use 5C-CPT; due to abuse liability. Genetic knockout of the α7 nicotinic acetylcholine receptor (nAChR) induces α 7 nAChR; attention deficits therefore selective agonism may improve attention, without the abuse liability Animal Model; associated with nicotine. The α7 nAChR partial agonist encenicline (formerly EVP-6124) enhances Behavioural separa- memory in rodents and humans. Here we investigate, for the first time, efficacy of encenicline to tion; Low attentive improve attention and vigilance in animals behaviourally grouped for low attentive traits in the 5 choice-continuous performance task (5C-CPT). Female Lister Hooded rats were trained to perform the5C-CPTwithavariablestimulusduration(SD).Animalswerethengroupedbasedonperformance intoupperandlowerquartilesofd0 (vigilance) and accuracy (selective attention), producing high- attentive (HA) and low-attentive (LA) groups. LA animals showed an increase in selective attention and vigilance at 0.3 mg/kg encenicline, a reduction in impulsive action (probability of false alarms) and increase in vigilance following 1 mg/kg at 0.75 s SD. At 1 mg/kg, HA animals had reduced selective attention at 0.75 s SD and reduced vigilance at 0.75 and 1.25 s SD.
    [Show full text]
  • Iatrogenic Misadventure
    BRITISH MEDICAL JOURNAL 18 MARcH 1972 733 Scientific Basis of Clinical Practice Br Med J: first published as 10.1136/bmj.1.5802.733 on 18 March 1972. Downloaded from Iatrogenic Misadventure A. G. W. WHITFIELD British Medical journal, 1972, 1, 733-734 effects. No one would pretend that our knowledge of drugs interacting with oral anticoagulants is complete. Even so, A striking feature of the history of therapeutics is the extent to sufficient is already known to indicate that anticoagulant drugs which fashion, rather than clinical science, governs the treat- have potent dangers and should be used only within the limited ment we mete out to our patients. Some ten years ago I attended sphere in which they are of proven worth. Moreover, when they a symposium on anticoagulant therapy and returned home are given, if possible, no other drug should be given at the firmly convinced that in all but a very few conditions such same time as many are known to inhibit or enhance their effect treatment was absolutely essential and indeed it was little short and many others may have similar interactions, even though of criminal negligence to withhold it. At that time the patient these are as yet unrecognized and unreported. queue for "prothrombin times" was usually the longest in our hospitals and phenindione was among the most frequently prescribed drugs, but our constant use of it stemmed from enthusiasm and ignorance of its dangers and not from scientific Hypotensive Drugs proof of its therapeutic advantages. Indeed it is only as know- Hypotensive drugs are being used increasingly and undoubtedly ledge has accumulated that we have learned of the toxic effects, their development has provided an enormous advance both in of the drug we gave so freely, on the kidney, the liver, the bone the treatment and in the prognosis of the severe forms of marrow, and the skin and that except in thromboembolic disease and in patients with hypertension-particularly in the younger age groups.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]